Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN V POTASSIUM versus TOTACILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN V POTASSIUM versus TOTACILLIN.
PENICILLIN V POTASSIUM vs TOTACILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin V is a bactericidal antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and activating autolytic enzymes.
Bactericidal: inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation. Active against gram-positive bacteria and some gram-negative bacteria.
250-500 mg orally every 6-8 hours.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours.
None Documented
None Documented
0.5-1 hour in patients with normal renal function; prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min). Clinical context: requires frequent dosing due to short half-life.
Terminal elimination half-life: 1.0-1.5 hours in normal renal function. Extended to 2-6 hours in renal impairment; requires dose adjustment when CrCl <30 mL/min.
Renal excretion of unchanged drug accounts for 20-40% of the dose via glomerular filtration and tubular secretion; biliary excretion is minor (<1%). Fecal elimination is negligible.
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <5% as unchanged drug and metabolites.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic